It was time to pay the piper for Stryker Corp. (NYSE:SYK) during the first quarter, as it ponied up about $46 million toward its $1.5 billion buyout of Boston Scientific’s (NYSE:BSX) neurovascular business.
Q1
Boston Scientific Q1 earnings: Analysts set modest goals for BSX
Analysts on Wall Street aren’t expecting heart-stopping numbers from cardiac device maker Boston Scientific (NYSE:BSX) when it releases its first-quarter earnings after the closing bell today.
Johnson & Johnson’s Q1 profits slides 23 percent as Synthes confirms merger talks
Johnson & Johnson (NYSE:JNJ) may have a monster fish on the hook, but it’s still got some work to do on its bottom line after watching its profits drop 23 percent during the first three months of 2011.